Abstract
Purpose: Comparison of efficacy and safety of combination therapy of photodynamic therapy (PDT) with Ranibizumab and Pegaptanib sodium respectively for subfoveal choroidal neovascularization in age-related macular degeneration. Design: Prospective, comparative, interventional case series. Materials and methods: Twenty patients received either PDT with 0.5 mg Ranibizumab (group 1; n = 10) or PDT with 0.3 mg Pegaptanib sodium (group 2; n = 10). Three doses of anti-VEGF injections were given monthly followed by reinjections pro re nata basis in both groups. Data recorded included visual acuity (VA), central macular thickness (CMT) by optical coherence tomography and greatest linear dimension (GLD) by angiography at 1 week, 1, 2, 3 and 6 months follow-up. Results: At 6 months follow-up, groups 1 and 2 showed 13.7 ± 10.25 and 2.8 ± 6.87 letters gain (p = 0.020), CMT decreased to 78.2 ± 61.28 μm and 13 ± 23.83 μm (p = 0.011) and decrease in GLD from baseline was 640 ± 687.6 μm and 584.0 ± 565.15 μm respectively (p = 0.971).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: World Journal of Retina & Vitreous
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
